Editors:
- Provides a comprehensive review of cancer nanotheranostics
- Represents the first book-length treatment of the topic
- Presents a full picture of the field, from basic research through clinical implementation
- Features evidence-based chapters with excellent illustrations and images to guide and assist the reader
Part of the book series: Bioanalysis (BIOANALYSIS, volume 5)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (18 chapters)
-
Front Matter
-
Introduction to Cancer and Nanotechnology
-
Front Matter
-
-
Cancer Nanodiagnostics and Nanotherapeutics
-
Front Matter
-
-
Regulatory Considerations for Nanomaterial Drug Products
-
Front Matter
-
-
Cancer Nanotheranostics
-
Front Matter
-
About this book
This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field.
Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for imaging contrast and therapy agents could provide unique breakthroughs in oncology. Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response and initiate secondary treatments if required. In oncology, chemotherapeutics have been routinely used. Some drugs have proven effective but all carry risks of adverse side effects. There is growing interest in using remotelytriggered drug delivery systems to limit cytotoxicity in the diseased area.
This book reviews the use of theranostic nanoparticles for cancer applications over the past decade. First, it briefly discusses the challenges and limitations of conventional cancer treatments, and presents an overview of the use of nanotechnology in treating cancer. These introductory chapters are followed by those exploring cancer diagnosis and a myriad of delivery methods for nanotherapeutics. The book also addresses multifunctional platforms, treatment monitoring, and regulatory considerations. As a whole, the book aims to briefly summarize the development and clinical potential of various nanotheranostics for cancer applications, and to delineate the challenges that must be overcome for successful clinical development and implementation of such cancer theranostics.
Editors and Affiliations
-
Department of Chemical Engineering, University of Massachusetts Lowell, Lowell, USA
Prakash Rai
-
National Cancer Institute, NIH Nanodelivery Systems and Devices Branch Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, Rockville, USA
Stephanie A. Morris
About the editors
Stephanie Morris, PhD joined the National Institutes of Health (NIH) as a Program Director at the National Cancer Institute in 2012 where she managed a portfolio of nanotechnology research projects and centers in the Alliance for Nanotechnology in Cancer program. She also developed new research initiatives such as the Innovative Research in Cancer Nanotechnology program and participated on several NIH and interagency committees and working groups, especially those focused on nanotechnology data sharing. She received her Bachelor's degree in Biology and Neuroscience and Behavior (dual majors) from WesleyanUniversity in Middletown, CT and her PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill where she was a Ford Foundation Fellow. She is also the recipient of a UNCF-Merck Postdoctoral Research Fellowship, which she received while in the National Cancer Institute's Laboratory of Receptor Biology and Gene Expression. Her research background includes the study of transcription and chromatin modifying enzymes. Dr. Morris recently moved to the Office of Strategic Coordination in the National Institutes of Health Office of the Director where she is involved in strategic planning for the NIH Common Fund and serves as a Program Officer for the Molecular Transducers of Physical Activity and the Somatic Cell Genome Editing programs.
Bibliographic Information
Book Title: Nanotheranostics for Cancer Applications
Editors: Prakash Rai, Stephanie A. Morris
Series Title: Bioanalysis
DOI: https://doi.org/10.1007/978-3-030-01775-0
Publisher: Springer Cham
eBook Packages: Engineering, Engineering (R0)
Copyright Information: This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019
Hardcover ISBN: 978-3-030-01773-6Published: 23 November 2018
eBook ISBN: 978-3-030-01775-0Published: 12 November 2018
Series ISSN: 2364-1118
Series E-ISSN: 2364-1126
Edition Number: 1
Number of Pages: XIV, 480
Number of Illustrations: 6 b/w illustrations, 83 illustrations in colour
Topics: Biomedical Engineering and Bioengineering, Oncology, Nanochemistry, Biomaterials, Pharmaceutical Sciences/Technology, Biological and Medical Physics, Biophysics